-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Zai Lab partner Paratek Pharmaceuticals recently announced that the U.
S.
Food and Drug Administration (FDA) has approved a supplementary new drug application (sNDA) for Nuzyra (omadacycline, omacycline tosylate, or "omacycline" for short).
): The oral-only dosing regimen of Nuzyra is used to treat adult patients with community-acquired bacterial pneumonia (CABP)
.
Previously, Nuzyra's administration regimen for CABP was an intravenous-oral regimen
Recently, the FDA also approved Nuzyra's oral dosing regimen for the treatment of acute bacterial skin and skin tissue infections (ABSSSI) in adult patients
.
Previously, Nuzyra's dosing regimen for the treatment of ABSSI was also an intravenous-oral regimen
Nuzyra was approved by the FDA in October 2018.
The drug is a modern tetracycline antibiotic that is administered orally or intravenously once a day for the treatment of CABP and ABSSSI
.
The newly approved oral-only dosing regimen will enable doctors to treat patients in outpatient or primary care facilities, reducing or eliminating the risks and costs during hospitalization and hospitalization
Omadacycline is a new type of 9-aminomethylcycline drug.
Note: The original text has been deleted